Stock Alert: NovaBay Pharma Shares Soar 42% In Early Trade

Shares of NovaBay Pharmaceuticals Inc. (NBY) are surging over 42% in pre-market today, after the company announced testing results from an independent third-party laboratory confirming that Avenova, NovaBay's proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

As previously announced, NovaBay continues to work with the U.S. FDA on the Emergency Use Authorization or EUA for the fluorecare SARS-CoV-2 IgG & IgM Antibody Combined Test Kit. The FDA has not provided a timeline for completion of the review, the company added.

The stock has been trading in the range of $0.24 - $1.85 for the past one year, and closed Friday's trade at $1.13, down 2 cents or 1.74%. NBY is currently trading at $1.62, up 48 cents or 42.11% in the pre-market session.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT